Research and Markets: Merck's October 2005 Announcement That Its Human Papillomavirus (HPV) Vaccine, Gardasil, Proved to Be 100% Effective in Preventing Cervical Cancer Has Excited the Medical Community but Has Also Triggered Debate
Posted on: Friday, 3 February 2006, 06:01 CST
Research and Markets (http://www.researchandmarkets.com/reports/c32240) has announced the addition of Pharmaceuticals and Politics: Will Political Opinion Affect the Future of HPV Vaccines? to their offering.
Human papillomavirus (HPV) is one of the most common sexually transmitted diseases and is responsible for the vast majority of cervical cancers worldwide. Treatment is a challenge because the immune response to the virus has not been well characterized, and the virus has a propensity to persist, produce recurrent clinical disease, and cause cancer. Merck's October 2005 announcement that its HPV vaccine, Gardasil, proved to be 100% effective in preventing cervical cancer has excited the medical community but has also triggered debate regarding its inclusion on the U.S. recommended schedule of vaccinations, an inclusion that is often critical for vaccines' commercial success.
This Decision Resources report reviews the prevalence of HPV; discusses Merck's Gardasil and GlaxoSmithKline's Cervarix HPV vaccines; profiles the U.S. Advisory Committee on Immunization Practices, which determines which vaccines are included on the U.S. recommended schedule of vaccinations; examines the debate surrounding the vaccines' inclusion on the U.S. recommended schedule of vaccinations; and discusses the implications of this debate for the pharmaceutical industry as a whole.
Topics covered in the report include:
-- The Impact of HPV on World Health
-- HPV and Its Connection to Cervical Cancer
-- Prevalence and Mortality Due to Cervical Cancer
-- The Advisory Committee on Immunization Practices
-- The Debate Surrounding HPV Vaccines
-- Impact on the Pharmaceutical Industry
For more information visit http://www.researchandmarkets.com/reports/c32240.
Source: Business Wire
Related Articles
- Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention
- MultiVu Video Feed: American Meat Institute Calls World Cancer Research Fund's Panel Recommendations on Meat Consumpton Extreme and Unfounded
- Mandates Complicate HPV Vaccine Debate
- Spanish Medical Societies Issue First European National Consensus Guidelines Recommending HPV DNA Testing for Cervical Cancer Screening
- HPV DNA Testing for Cervical Cancer
- ADDING and REPLACING FDA Approves Merck's GARDASIL(R), the World's First and Only Cervical Cancer Vaccine; GARDASIL Prevents Cervical Cancer, Precancerous and Low-Grade Lesions and Genital Warts Caused By HPV Types 6, 11, 16 and 18
- FDA Panel Endorses Vaccine to Prevent Cervical Cancer
- Vaccine for Cancer Finds a Patron
- Measles Vaccines Arrive in Nigeria for World's Biggest Vaccination Campaign: WHO
- Research and Markets: Therapeutic Vaccines for Cancer: On the Threshold of Success
 |
 |
User Comments (0)
RSS Feeds